Excellence in Pediatrics is a non-profit association dedicated to advancing pediatric healthcare.
Rue des Vignerons 18, 1110 Morges 1 (VD), Switzerland
email: secretariat@ineip.org
tel. +41 43 21 55 937
This Issue
Following the strong response to our first CLN2 session, the Think Rare Program continues with a live webinar on the differential diagnosis of CLN2 (Batten disease) featuring two leading pediatric neurologists.
Context
Children with CLN2 are often diagnosed years after their first symptoms appear. Early signs like language delay, seizures, and clumsiness can look like epilepsy, autism, or general developmental delay, so CLN2 often goes unrecognized until much later, when more symptoms appear and the picture becomes harder to ignore.
That delay matters. CLN2 progresses quickly, and the earlier it’s recognized, the more options remain open for families and clinicians alike.
This webinar in the Think Rare series, taking place on 15 July and presented by Dr. Marina Trivisano and Dr. Pasquale Striano, helps clinicians recognize when a familiar diagnosis no longer fits the full picture, and when it’s time to test for CLN2 rather than continue down a more common pathway.
Upcoming Webinar 2 • Wednesday, 15 July
Key Learning Points from the Webinar
At the end of the webinar, participants will be able to:
Diagnostic Pathways That Delay Recognition
Understand how common diagnostic pathways can delay recognition of CLN2 disease.
Red Flags and Progression Patterns
Identify red-flag symptom combinations that justify escalation beyond common diagnoses.
When to Refer and When to Test
Initiate prompt referral and genetic testing in suspected CLN2, aligned with clinical suspicion.
Now Open for Registration • Webinar 3
Multidisciplinary Management and Treatment in CLN2 (Batten Disease)
Wednesday, 9th September 2026 · 13:00 CEST
This webinar will address the practical management of CLN2 disease, a rare and rapidly progressive neurodegenerative condition where early diagnosis directly influences treatment opportunities and long-term care planning. Led by Dr. Dipak Ram, the session will focus on current treatment approaches, including enzyme replacement therapy, alongside supportive and symptomatic care across the disease trajectory.
Register for Webinar 3 →Catch Up • Webinar 1
Disclaimer
These webinars are intended for healthcare professionals only. These are promotional webinars sponsored and funded by BioMarin. BioMarin medicines will be discussed.
All adverse event(s) discussed will be notified to the Pharmacovigilance Department of BioMarin. BioMarin does not recommend the use of any product in any manner other than that described in the approved Prescribing Information. Regulatory status and approved indications of any product may vary between countries; please check the registration status of any product in your respective country.
About the Program
The EiP Think Rare Program empowers pediatricians and general practitioners to identify rare and underdiagnosed conditions early. The program currently covers MPS, MLD, and AM, and is now expanding to CLN2 (Batten disease).
The THINK RARE program is independently developed and managed by EiP, including content, topics, and appointed speakers. BioMarin has sponsored and funded EiP’s webinars on CLN2.
COM-ET-2512
Rue des Vignerons 1B, 1110 Morges (VD), Switzerland
secretariat@ineip.org
